GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Paradigm Biopharmaceuticals PAR.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Paradigm Biopharmaceuticals — daily ASX:PAR

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Paradigm Biopharmaceuticals on TradingView ↗

About Paradigm Biopharmaceuticals

Its shares trade on ASX under the ticker PAR.AX. It has been listed since 19 August 2015. In the fiscal year to 30 June 2025, it reported revenue of A$7.1m and a net loss of A$18.8m. At that date it held total assets of A$24.6m and shareholders' equity of A$21.2m.

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The company is engaged in researching and developing therapeutic products for human use. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).

Figures and description from our data supplier, not checked against the company's own report.

More about Paradigm Biopharmaceuticals →

Latest on Paradigm Biopharmaceuticals

Our reporting

We have not reported on Paradigm Biopharmaceuticals yet.

Next results

24 Feb 2027

Due on 24 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Paradigm Biopharmaceuticals's ticker?

Paradigm Biopharmaceuticals trades as PAR.AX on ASX, under ISIN AU000000PAR5.

What was Paradigm Biopharmaceuticals's last closing price?

We have not recorded a close for this listing yet. The chart above carries pricing from TradingView.

When does Paradigm Biopharmaceuticals next report results?

Results are expected on 24 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.